Sign up Australia
Proactive Investors - Run By Investors For Investors

Auscann Group makes steady progress towards production of cannabinoid medicines

Auscann has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.
cannabis medicines
Partners include industry leaders such as Canopy Growth Corp and Fundacion Daya

Auscann Group Holdings Ltd (ASX:AC8) is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019.

The company has established several strategic partnerships in Australia, Chile and Canada and is advancing its position as a fully-integrated cannabinoid pharmaceutical company.

READ: AusCann Group well positioned as investors move in on medical cannabis sector

During the year ended June 30, 2018, the company achieved important milestones across its operations, including new agreements, R&D breakthroughs and regulatory advances.

Post FY2018, Auscann raised over $35 million and remains well-funded to continue executing its strategic goals.

READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

AusCann managing director Elaine Darby said: “Progress has been made across all aspects of the company’s operations during this financial year.

“We are now several steps closer to our goal of providing patients with access to high-quality, economical and clinically-validated cannabinoid medicines.

“I’d like to personally thank all shareholders for their continued support and we look forward to delivering on our commitment to releasing our first medicinal cannabis products in 2019.”

READ: AusCann Group pilot study reveals unique capsule for cannabinoid medicines

AusCann aims to produce high quality, economical and clinically validated cannabinoid medicines.

It has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products.

This is made possible through a number of partnerships with industry leaders such as Canopy Growth Corp and Fundacion Daya.

The company is initially targeting medications for neuropathic and chronic pain in Australia and internationally, a market estimated to be worth $9 billion in Australia alone.

Upcoming ASX Small and Mid-Cap Conference

AusCann will be presenting at the inaugural ASX Small and Mid-Cap Conference being held in Sydney on Thursday, September 6.

To attend the conference, please register here.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use